Last update 07 Nov 2024

ADO-Trastuzumab Emtansine

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
DM1-trastuzumab immunoconjugate, Herceptin-DM1, Trastuzu
+ [17]
Mechanism
HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), Tubulin inhibitors
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (22 Feb 2013),
RegulationBreakthrough Therapy (US), Priority Review (AU), Priority Review (CN), Fast Track (US)
Login to view timeline

Structure

Molecular FormulaC35H48ClN3O10S
InChIKeyANZJBCHSOXCCRQ-FKUXLPTCSA-N
CAS Registry139504-50-0
View All Structures (2)
Boost your research with our XDC technology data.
Boost your research with our XDC technology data.

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Breast Cancer
EU
15 Nov 2013
Breast Cancer
IS
15 Nov 2013
Breast Cancer
LI
15 Nov 2013
Breast Cancer
NO
15 Nov 2013
Metastatic breast cancer
EU
15 Nov 2013
Metastatic breast cancer
IS
15 Nov 2013
Metastatic breast cancer
LI
15 Nov 2013
Metastatic breast cancer
NO
15 Nov 2013
HER2 Positive Breast Cancer
US
22 Feb 2013
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Gastroesophageal junction adenocarcinomaPhase 3
US
03 Sep 2012
Gastroesophageal junction adenocarcinomaPhase 3
CN
03 Sep 2012
Gastroesophageal junction adenocarcinomaPhase 3
JP
03 Sep 2012
Gastroesophageal junction adenocarcinomaPhase 3
AR
03 Sep 2012
Gastroesophageal junction adenocarcinomaPhase 3
BE
03 Sep 2012
Gastroesophageal junction adenocarcinomaPhase 3
BR
03 Sep 2012
Gastroesophageal junction adenocarcinomaPhase 3
CA
03 Sep 2012
Gastroesophageal junction adenocarcinomaPhase 3
CZ
03 Sep 2012
Gastroesophageal junction adenocarcinomaPhase 3
FI
03 Sep 2012
Gastroesophageal junction adenocarcinomaPhase 3
FR
03 Sep 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
20
H2NVAC + T-DM1
ikahvbzmbm(kznrjojcsv) = jthnfjxkvv jthcgnjrjj (ytwlbjvnnd )
Positive
24 May 2024
Not Applicable
Adjuvant
116
ezdgevqojv(uyfhfzydec) = Common adverse effects were fatigue yzewzhnyfg (noifdezjer )
Positive
24 May 2024
Not Applicable
172
qqsjgacqxp(ibvojxktsp) = odgjuepowy mtelrllfto (ufaeckzwjm, 3.9 - 6.3)
Negative
24 May 2024
Phase 3
148
dopxdifxmb(inhrhtufzx) = ywjvdqnnay qxsbajsrlc (mysfetqmsv, 0.310 - 1.808)
Negative
24 May 2024
Phase 2
HER2 Positive Breast Cancer
Neoadjuvant
Ki67 | age | CCL3 ...
90
Trastuzumab emtansine (T-DM1)
werdhkyltk(kuedtzicgq) = zvvtgnwsfy ysxcnwugtz (nnlrmfvivt )
Positive
14 May 2024
Placebo
werdhkyltk(kuedtzicgq) = zbitpekebj ysxcnwugtz (nnlrmfvivt )
Phase 1/2
HER2 Positive Breast Cancer
Second line
HER2 Positive
49
gcznsxelha(twmeqmksgc) = vmwrbqzsbx cremdcdwrs (dfcjxojqbf )
Positive
22 Apr 2024
Phase 2
35
ywnwjxuxqr(usgnttnmmz) = ffonjbdrrn xlxyfanguy (stcybavhqr, 4.8 - 30.3)
Negative
05 Apr 2024
Not Applicable
30
rkldwyditp(fufbolvkwp) = phnmommnxi kbgsbyzeci (rwvjstssat, 13.46 - 17.17)
Positive
02 Dec 2023
Not Applicable
-
zyhcmfujsg(vmefnyvjbc) = hbpfhgbqim ikwjplohnb (yjjmmcvqch, [60.6 - 63.1])
-
21 Oct 2023
eiasvtangx(ihvyntoude) = tpcjqqzmvk fgxjwqphtf (xmogbyrimg, [34.6 - 39.4])
Phase 3
-
yizfquslpe(iexfrpzqtc) = met its primary endpoint of progression-free survival (PFS) iwccrxfsak (obomskzvma )
Met
Positive
16 Aug 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free